Last reviewed · How we verify
NCT04362943: COVID-AGE
Clinical-epidemiological Characterization of COVID-19 Disease in Hospitalized Older Adults
trial testing Baricitinib or Anakinra in COVID-19 in 576 participants. Completed in 15 April 2021.
15 April 2021
Quick facts
| Lead sponsor | Complejo Hospitalario Universitario de Albacete |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 576 |
| Start date | 20 April 2020 |
| Primary completion | 15 April 2021 |
| Estimated completion | 15 April 2021 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- Baricitinib or Anakinra — full drug profile →
Conditions studied
- COVID-19 — all drugs for COVID-19 →
Sponsor
Complejo Hospitalario Universitario de Albacete
Who can join
70 and older, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Retrospective clinical-epidemiological study aimed at characterizing COVID-19 disease in adults older than 70 years, hospitalized in the "Perpetuo Socorro" Hospital of Albacete (Spain) from 09/03/2020 until 20/04/2020. Secondary objectives will be to analyze clinical-epidemiological characteristics of COVID-19 patients treated with Baricitinib or Anakinra, and to describe the efficacy and secondary effects of those drugs.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19.
Luo W, Li YX, Jiang LJ, Chen Q, et al · · 2020 · cited 217× · PMID 32580895 · DOI 10.1016/j.tips.2020.06.007 -
JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality.
Stebbing J, Sánchez Nievas G, Falcone M, Youhanna S, et al · · 2021 · cited 164× · PMID 33187978 · DOI 10.1126/sciadv.abe4724 -
Baricitinib: A Review of Pharmacology, Safety, and Emerging Clinical Experience in COVID-19.
Jorgensen SCJ, Tse CLY, Burry L, Dresser LD. · · 2020 · cited 142× · PMID 32542785 · DOI 10.1002/phar.2438 -
JAK-STAT Pathway Inhibition and their Implications in COVID-19 Therapy.
Satarker S, Tom AA, Tom AA, Shaji RA, et al · · 2021 · cited 117× · PMID 33245005 · DOI 10.1080/00325481.2020.1855921 -
Targeting GM-CSF in COVID-19 Pneumonia: Rationale and Strategies.
Bonaventura A, Vecchié A, Wang TS, Lee E, et al · · 2020 · cited 112× · PMID 32719685 · DOI 10.3389/fimmu.2020.01625 -
Repurposing of Kinase Inhibitors for Treatment of COVID-19.
Weisberg E, Parent A, Yang PL, Sattler M, et al · · 2020 · cited 106× · PMID 32778962 · DOI 10.1007/s11095-020-02851-7 -
Short linear motif candidates in the cell entry system used by SARS-CoV-2 and their potential therapeutic implications.
Mészáros B, Sámano-Sánchez H, Alvarado-Valverde J, Čalyševa J, et al · · 2021 · cited 69× · PMID 33436497 · DOI 10.1126/scisignal.abd0334 -
Vasculopathy and Coagulopathy Associated with SARS-CoV-2 Infection.
Labò N, Ohnuki H, Tosato G. · · 2020 · cited 57× · PMID 32629875 · DOI 10.3390/cells9071583
Verify or expand the search:
- PubMed search for NCT04362943
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Other Complejo Hospitalario Universitario de Albacete trials
Trials by the same sponsor.
- NCT06583824 — Incidence and Complications of Post-extubation and Post-tracheostomy Dysphagia in Adult Patients in the Critical Care Un · not yet recruiting
- NCT06279910 — Calcifediol in the Treatment of SARS-CoV-2 Disease (COVID-19). · completed
- NCT05104593 — An Integrated Solution for Sustainable Care for Multimorbid Elderly Patients With Dementia · NA · unknown
- NCT05879263 — "Efficacy of Intermittent Enteral Nutrition Versus Continuous Administration in Intensive Care" · NA · unknown
- NCT05002439 — RCT to Analyze the Efficacy of a Spanish Healthcare ministRy Based In InTervention to Reduce Frailty Status in Prefrail · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04362943 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Complejo Hospitalario Universitario de Albacete
- Last refreshed: 28 July 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04362943.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing